INT265925

From wiki-pain
Revision as of 23:05, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 5
Disease Relevance 2.62
Pain Relevance 0.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
capsule 2
body 1
Clas4 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 40 59.60 Quite High
Pain 5 57.88 Quite High
rheumatoid arthritis 75 47.12 Quite Low
cINOD 10 44.40 Quite Low
agonist 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Body Weight 15 98.96 Very High Very High Very High
Disorder Of Lipid Metabolism 115 98.32 Very High Very High Very High
Cardiovascular Disease 50 88.04 High High
Hyperlipidemia 10 80.20 Quite High
Coronary Artery Disease 10 77.92 Quite High
Myocardial Infarction 10 77.36 Quite High
Nicotine Addiction 10 75.84 Quite High
Obesity 60 69.72 Quite High
INFLAMMATION 45 59.60 Quite High
Arthralgia 5 58.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The absence of such effects of CLAs supplementation should not be attributed to the interference of weight, physical activity, dietary intake or medication because these variables did not change during the study period and the patients had good compliance in taking their supplements. ?
Gene_expression (supplementation) of CLAs
1) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663461 Disease Relevance 0.72 Pain Relevance 0
However some studies have reported that CLAs supplementation (4 g/d) had no effect on body weight, but they significantly reduced body fat (Smedman and Vessby 2001).
Gene_expression (supplementation) of CLAs in body associated with body weight
2) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663461 Disease Relevance 0.29 Pain Relevance 0
CLAs was prescribed 2 g daily as 2 capsules (each capsule was 1.25 g and contained 80% CLAs) containing both cis-9, trans-11 CLAs and trans-10, cis-12 triglyceride type CLAs in equal proportion and vitamin E (?
Gene_expression (trans) of CLAs in capsule
3) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663461 Disease Relevance 0.65 Pain Relevance 0.08
CLAs was prescribed 2 g daily as 2 capsules (each capsule was 1.25 g and contained 80% CLAs) containing both cis-9, trans-11 CLAs and trans-10, cis-12 triglyceride type CLAs in equal proportion and vitamin E (?
Gene_expression (contained) of CLAs in capsule
4) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663461 Disease Relevance 0.67 Pain Relevance 0.09
Several other studies have shown no deleterious effects on glucose or insulin levels or sensitivity to insulin attributable to the consumption of different doses of CLAs enriched with cis 9, trans 11 or trans 10, cis 12 (Tricon et al 2004; Taylor and Zahradka 2004).
Gene_expression (enriched) of CLAs
5) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663461 Disease Relevance 0.30 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox